Novartis | NOVN - Equity Capital And Reserves



Novartis reported $42.05B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Alcon AG USD 22.13B 111M Jun/2025
Almirall EUR 1.46B 37.19M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Autolus Therapeutics Ltd 346.46M 24.64M Jun/2025
Bayer EUR 30.5B 2.08B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
Fresenius EUR 18.94B 465M Jun/2025
Fresenius Medical Care EUR 14.33B 1.18B Jun/2025
Galapagos EUR 2.64B 104.07M Jun/2025
Genmab DKK 5.3B 6M Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
GRIFOLS EUR 7.6B 1.96B Jun/2025
Hikma Pharmaceutical USD 2.32B 35M Dec/2024
J&J USD 78.11B 6.62B Mar/2025
Lonza CHF 9.33B 23M Dec/2024
Merck EUR 28.26B 1.64B Jun/2025
Merck USD 49.06B 725M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Novartis USD 42.05B 1.99B Jun/2025
Novo Nordisk 168.07B 29.53B Jun/2025
Orion EUR 919.6M 147.2M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Philips EUR 10.38B 1.32B Jun/2025
Recordati EUR 1.87B 107.18M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
UCB EUR 10.03B 1.08B Dec/2024